Magnesium Treatment in Hypoparathyroidism

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vallo Volke, University of Tartu
ClinicalTrials.gov Identifier:
NCT00824226
First received: January 15, 2009
Last updated: August 26, 2011
Last verified: August 2011

January 15, 2009
August 26, 2011
January 2009
August 2011   (final data collection date for primary outcome measure)
Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00824226 on ClinicalTrials.gov Archive Site
Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Magnesium Treatment in Hypoparathyroidism
Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypoparathyroidism
Dietary Supplement: magnesium
magnesium 350 mg tablets once a day for 3 weeks
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • primary or secondary hypoparathyroidism
  • treatment with calcium plus vitamin D analogue
  • ionized calcium 1,0-1,29 mmol/L
  • magnesium level 0,7-1,05 mmol/L
  • TSH 0.1- 10 imU/L

Exclusion Criteria:

  • any other disease known to influence plasma Ca level
  • pregnancy
  • creatinine > 150 microM/L
  • patient has used supplementary magnesium within 2 previous months
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Estonia
 
NCT00824226
UT296
No
Vallo Volke, University of Tartu
University of Tartu
Not Provided
Principal Investigator: Vallo Volke, MD, PhD University of Tartu, Institute of Physiology
University of Tartu
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP